FUL.L Regulatory News (FUL)

11 Oct 2007 07:01

Fulcrum Pharma PLC11 October 2007 FULCRUM PHARMA PLC ("the Group" or "the Company") Fulcrum wins contract to execute a phase III clinical oncology project in Japan Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory servicescompany is pleased to announce that its Japanese subsidiary has won a contractto execute a phase III clinical oncology development study in Japan on behalf ofa major Pharma company. The project runs from September 2007 for four years andis worth over 600 million JPY (over £2.5 million) in fees. In conjunction withother contracts already secured, this contract will mean that at currentcapacity, Fulcrum's Japanese subsidiary has a virtually full order book for thenext two years. Fulcrum has established itself in Japan as a specialist oncology clinicalresearch organization where it now conducts studies for a range of Japanesecompanies, global pharma and Japanese government funded academic groups. Alastair Devlin, Director of Japanese Strategy of Fulcrum Pharma, said: "We aredelighted to win this contract with a major Pharma company which has recognisedour strength in oncology. Cancer is the leading cause of death in Japan which isthe world's largest oncology market." For further information, please contact: Fulcrum Pharma PLCJon Court, Chief Executive Tel: 0870 710 7152 Seymour PierceJonathan Wright Tel: 0207 107 8000 About Fulcrum Pharma plc Fulcrum Pharma plc is a drug development and regulatory services business thatprovides global expertise to achieve drug development and regulatory approvalmilestones. Fulcrum Pharma offers immediate access to a highly credible, integrateddevelopment team that provides strategic and operational leadership required toensure that new drugs move smoothly from discovery research to product approval Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange This information is provided by RNS The company news service from the London Stock Exchange